We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Edgewise Therapeutics Inc (EWTX) USD0.0001

Sell:$17.85 Buy:$17.88 Change: $0.72 (4.21%)
Market closed |  Prices as at close on 12 June 2024 | Switch to live prices |
Change: $0.72 (4.21%)
Market closed |  Prices as at close on 12 June 2024 | Switch to live prices |
Change: $0.72 (4.21%)
Market closed |  Prices as at close on 12 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.

Contact details

1715 38Th St
United States
+1 (720) 2627002

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.60 billion
Shares in issue:
93.28 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Kevin Koch
    President, Chief Executive Officer, Director
  • Alan Russell
    Chief Scientific Officer, Director, Co-Founder
  • R. Michael Carruthers
    Chief Financial Officer
  • John Moore
    General Counsel
  • Behrad Derakhshan
    Chief Business Officer
  • Joanne Donovan
    Chief Medical Officer
  • Marc Semigran
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.